CorMedix Inc (NASDAQ:CRMD - Get Free Report) has received an average rating of "Moderate Buy" from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $15.22.
CRMD has been the topic of a number of recent research reports. UBS Group set a $19.00 target price on CorMedix in a report on Tuesday, November 10th. Oppenheimer reiterated an "outperform" rating and set a $13.00 price target (down from $15.00) on shares of CorMedix in a report on Friday, November 13th. Citigroup reiterated a "market outperform" rating on shares of CorMedix in a report on Tuesday, November 10th. Weiss Ratings lowered CorMedix from a "hold (c+)" rating to a "hold (c)" rating in a research report on Tuesday, November 10th. Finally, Needham & Company LLC raised their price objective on CorMedix from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Tuesday, November 10th.
Check Out Our Latest Stock Analysis on CorMedix
Insider Activity
In other news, Director Myron Kaplan acquired 25,000 shares of CorMedix stock in a transaction on Monday, November 16th. The stock was acquired at an average cost of $4.88 per share, with a total value of $122,000.00. Following the transaction, the director owned 256,487 shares of the company's stock, valued at approximately $1,251,656.56. This trade represents a 10.80% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph Todisco acquired 80,000 shares of the firm's stock in a transaction on Friday, November 13th. The stock was purchased at an average price of $4.89 per share, with a total value of $391,200.00. Following the purchase, the chief executive officer owned 854,749 shares in the company, valued at approximately $4,179,722.61. The trade was a 10.33% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 121,500 shares of company stock worth $588,195 over the last quarter. Insiders own 3.50% of the company's stock.
Hedge Funds Weigh In On CorMedix
Hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. increased its position in shares of CorMedix by 688.5% during the 3rd quarter. American Century Companies Inc. now owns 2,722,920 shares of the company's stock valued at $20,966,000 after purchasing an additional 2,377,579 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in shares of CorMedix by 38.6% in the 3rd quarter. Kestra Advisory Services LLC now owns 17,950 shares of the company's stock worth $138,000 after buying an additional 5,000 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in shares of CorMedix in the 3rd quarter worth about $196,000. Goldman Sachs Group Inc. boosted its holdings in shares of CorMedix by 167.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company's stock worth $9,620,000 after buying an additional 782,989 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in CorMedix during the third quarter valued at about $332,000. Hedge funds and other institutional investors own 34.18% of the company's stock.
CorMedix Stock Up 3.7%
Shares of NASDAQ CRMD opened at $5.27 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.43 and a quick ratio of 2.36. The company has a 50-day moving average price of $6.86 and a 200-day moving average price of $7.49. The stock has a market capitalization of $419.18 million, a P/E ratio of 7.64, a P/E/G ratio of 1.21 and a beta of 1.48. CorMedix has a 1 year low of $4.47 and a 1 year high of $13.02.
CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. On average, equities research analysts forecast that CorMedix will post 0.44 EPS for the current fiscal year.
CorMedix Company Profile
(
Get Free Report)
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.